Arcus Biosciences (RCUS) Total Non-Current Liabilities (2017 - 2026)

Arcus Biosciences' Total Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $878.0 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 15.09% year-over-year to $878.0 million in Q1 2026; TTM through Mar 2026 was $878.0 million, a 15.09% decrease from a year earlier, with the FY2025 full-year figure at $1.0 billion, up 1.11% from the prior year.
• Total Non-Current Liabilities eased to $878.0 million in Q1 2026 per RCUS's latest filing, from $1.0 billion in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $1.2 billion in Q3 2024 and bottomed at $679.0 million in Q3 2022.
• The 5-year median for Total Non-Current Liabilities is $1.0 billion (2025), against an average of $970.8 million.
• Across the five-year window, Total Non-Current Liabilities surged 181.77% in 2022 and fell 29.38% in 2025, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $1.2 billion in 2022, then retreated by 17.84% to $953.0 million in 2023, then increased by 4.2% to $993.0 million in 2024, then rose by 1.11% to $1.0 billion in 2025, then decreased by 12.55% to $878.0 million in 2026.
• Per Business Quant, the three latest RCUS Total Non-Current Liabilities figures stand at $878.0 million (Q1 2026), $1.0 billion (Q4 2025), and $822.0 million (Q3 2025).